Dasatinib Monohydrate: Multitargeted Tyrosine Kinase Inhibitor in Leukemia Research

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a potent, ATP-competitive multitargeted kinase inhibitor that targets ABL, SRC, KIT, PDGFR, and other tyrosine kinases [APExBIO]. It demonstrates nanomolar IC50 values (0.55 nM for SRC, 3.0 nM for BCR-ABL) under standard kinase assay conditions (Telerman et al., 2022). Dasatinib is effective against both nonmutated and imatinib-resistant BCR-ABL isoforms, making it integral for chronic myeloid leukemia (CML) research and resistance mechanism studies. Clinically, it has been FDA-approved since 2006 for all phases of Philadelphia chromosome-positive leukemias. In vivo, dasatinib significantly reduces disease progression and bioluminescent tumor signals in mouse models of BCR-ABL-driven malignancy.

Biological Rationale

Chronic myeloid leukemia (CML) is primarily driven by the BCR-ABL1 fusion gene, resulting from the Philadelphia chromosome translocation (Telerman et al., 2022). This chimeric protein encodes a constitutively active tyrosine kinase, leading to uncontrolled cell proliferation. Inhibition of BCR-ABL1 kinase activity is the central therapeutic strategy for CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). However, resistance to first-generation inhibitors (e.g., imatinib) has prompted the development of multitargeted kinase inhibitors such as Dasatinib Monohydrate. Dasatinib’s broad spectrum activity supports its use in research models investigating both canonical and noncanonical kinase signaling pathways, including SRC-family kinases and PDGFR. This compound also serves as a reference for dissecting the role of tyrosine kinase signaling in hematological and solid tumor microenvironments.

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate is a reversible, ATP-competitive inhibitor. It binds to the active and inactive conformations of ABL kinase domains, including BCR-ABL and its clinically relevant mutants. The compound exhibits high potency (IC50 = 3.0 nM for BCR-ABL, 0.55 nM for SRC) in in vitro kinase assays (Telerman et al., 2022). By inhibiting SRC-family kinases, Dasatinib blocks downstream signaling pathways involved in cell proliferation, migration, and survival. It also targets additional tyrosine kinases—KIT and PDGFR—thereby expanding its utility beyond BCR-ABL-driven malignancies. In cell-based models, Dasatinib induces apoptosis and cell cycle arrest in both hematological and solid tumor lines. Importantly, Dasatinib is active against imatinib-resistant BCR-ABL mutants, including those with ATP-binding site alterations.

Evidence & Benchmarks

• Dasatinib Monohydrate inhibits BCR-ABL kinase with an IC50 of 3.0 nM in standard biochemical assays (Telerman et al., 2022, DOI).
• SRC kinase is inhibited with an IC50 of 0.55 nM (Telerman et al., 2022, DOI).
• In vitro, Dasatinib demonstrates broad-spectrum antiproliferative effects in CML and solid tumor cell lines (Telerman et al., 2022, DOI).
• Dasatinib is effective against both wild-type and imatinib-resistant BCR-ABL isoforms (Telerman et al., 2022, DOI).
• In vivo administration in mouse models reduces disease progression and bioluminescent tumor activity (Telerman et al., 2022, DOI).

For a detailed mechanistic comparison, see Next-Generation Precision Oncology: Leveraging Dasatinib, which discusses assembloid modeling for translational research; this article extends that discussion by providing updated pharmacological benchmarks and resistance insights. Dasatinib Monohydrate in Next-Generation Tumor Microenvironment Modeling explores tumor-stroma interactions, whereas the present article clarifies clinical and biochemical efficacy thresholds. For workflow specifics, see Advancing Kinase Inhibition in Personalized Cancer Models, contrasted here with new evidence of in vivo disease suppression.

Applications, Limits & Misconceptions

Dasatinib Monohydrate is primarily used in:

• Chronic Myeloid Leukemia (CML) research, including drug resistance and kinase signaling pathway studies.
• Modeling Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
• Exploring SRC family kinase pathways in solid tumors.
• Preclinical in vitro and in vivo studies of kinase inhibitor efficacy and resistance.

Misconceptions may arise regarding its selectivity, clinical translation, and off-target effects.

Common Pitfalls or Misconceptions

• Dasatinib is not selective for BCR-ABL alone; it inhibits multiple kinases, which can confound pathway-specific conclusions.
• It is ineffective in models with kinase-independent resistance mechanisms.
• Dasatinib is insoluble in water and ethanol; improper solvent choice leads to precipitation and loss of activity.
• Long-term solutions (>1 week) at room temperature or 4°C result in significant degradation; always store at -20°C and use fresh solutions for reproducibility (per APExBIO specifications).
• Pharmacological results in mouse models may not fully predict human toxicity profiles, especially regarding vascular or cardiovascular side effects.

Workflow Integration & Parameters

Dasatinib Monohydrate (SKU: B5954) is supplied as a solid with a molecular weight of 506.02 (C₂₂H₂₈ClN₇O₃S). It is soluble at concentrations ≥25.3 mg/mL in DMSO and insoluble in ethanol or water. For optimal stability, store at -20°C and prepare working solutions immediately prior to use. Typical in vitro assay concentrations range from 0.1 nM to 1 μM, with exposure times of 6–72 hours, depending on cell type and endpoint. For in vivo studies, dosing should be referenced against published mouse models (e.g., 10–50 mg/kg/day oral gavage), always considering local ethical guidelines and pharmacokinetic parameters. APExBIO recommends short-term use of DMSO solutions to minimize compound degradation (Dasatinib Monohydrate product page).

Conclusion & Outlook

Dasatinib Monohydrate is a central tool for dissecting tyrosine kinase signaling and resistance mechanisms in leukemia and solid tumor models. Its multitargeted activity and proven efficacy against imatinib-resistant BCR-ABL make it an essential reference for translational research. Ongoing studies continue to evaluate its mechanistic roles and safety profile, particularly in relation to vascular toxicity and off-target pathway modulation (Telerman et al., 2022). For comprehensive product details and ordering, consult the APExBIO Dasatinib Monohydrate resource.